Source comparison
Does Tesamorelin Help Andropause Research: Comparison of Hormonal Interventions
Tesamorelin 2mg daily GHRH receptor agonist → pulsatile GH release 15.2% mean reduction (CT-verified) Neutral to slight increase Transient mild elevation in 6% of subjects, resolves without intervention Isolates GH-axis effects; useful for studying body compos
This comparison does not assign a generated winner or score.
- Tesamorelin 2mg daily
- GHRH receptor agonist → pulsatile GH release
- 15.2% mean reduction (CT-verified)
- Neutral to slight increase
- Transient mild elevation in 6% of subjects, resolves without intervention
- Isolates GH-axis effects; useful for studying body composition independent of testosterone
- Testosterone cypionate 100mg weekly
- Androgen receptor agonism
- 8–12% reduction (secondary to lean mass increase and metabolic rate elevation)
- Significant increase (3–5kg over 6 months)
- Minimal—may improve insulin sensitivity in hypogonadal men
- Primary andropause intervention; does not address GH decline
- Exogenous GH 2IU daily
- Direct GH receptor activation
- 10–14% reduction
- Moderate increase
- High risk—fasting glucose elevated in 18–25% of subjects, dose-limiting
- Research use limited by hyperglycemia risk; tesamorelin safer alternative
- Metformin 1000mg twice daily
- AMPK activation, hepatic glucose suppression
- 3–6% reduction (modest, primarily subcutaneous)
- Neutral
- Improves insulin sensitivity
- Addresses metabolic component but not hormonal axis decline